Cancer vaccine therapy using epitope peptide from CDH3 restricted to HLA-A*2402 with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancer (Phase I study)

Cancer vaccine therapy using epitope peptide from CDH3 restricted to HLA-A*2402 with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancer (Phase I study) - Cancer vaccine therapy using epitope peptide from CDH3 restricted to HLA-A*2402 with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancer (Phase I study)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005549

Enrollment

Registered

2011-05-03

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

vaccination using epitope peptide from CDH3 restricted to HLA-A*2402 with gemcitabine chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who have unresectable advanced pancreatic cancer 2)The presence or absence of measurable or evaluable lesions by RECIST was not taken into account. 3)Performance status (ECOG) of the patients are 0-2. 4)more than 20, less than 80 years of age. 5)Patients who can expect the survival of three months or more. 6)Patients who have undergone operation, and recovered the influence by surgery. Or two weeks or more have passed since pre-medical treatment. 7)without dysfunction of multiple major organs 8)with HLA-A*2402 9)Patients who have not been treated with gemcitabine. 10)All patients gave written informed consent.

Exclusion criteria

Exclusion criteria: 1)Pregnancy or lactation 2)Patients with the intention of pregnancy. 3)Patients have uncontrollable severe infectional diseases. 4)Patients who are treated with steroid or immunotherapy during clinical trial. 5)Patients have uncontrollable multiple cancer. 6)Patients who have non-recovered injury. 7)Patients who have ileus and interstitial lung disiease. 8)Patients whom doctors define as inappropriate.

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Immunological response, Antitumor efficacy, Time to progression, Overall survival	—

Countries

Japan

Contacts

Public ContactMasayo Hosokawa

Sapporo Medical University 1st Department of Internal Medicene

011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026